Related Experiment Video

Updated: May 20, 2026

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice
08:43

Adoptive Immunotherapy of iNKT Cells in Glucose-6-Phosphate Isomerase (G6PI)-Induced RA Mice

Published on: January 31, 2020

Targeting of TAK1 in inflammatory disorders and cancer

Hiroaki Sakurai1

  • 1Department of Cancer Cell Biology, Graduate School of Medicine and Pharmaceutical Sciences, University of Toyama, Toyama 930-0194, Japan. hsakurai@pha.u-toyama.ac.jp

Trends in Pharmacological Sciences
|July 17, 2012
PubMed

Insights

Transforming growth factor-β-activated kinase 1 (TAK1) is crucial for stress, immunity, and inflammation responses. Targeting TAK1 offers potential new therapies for inflammatory diseases and cancer.

Area of Science:

  • Molecular Biology
  • Cell Signaling
  • Immunology

Background:

  • Nuclear factor-κB (NF-κB) and activating protein-1 (AP-1) are key transcription factors in stress, immunity, inflammation, and cancer.
  • Transforming growth factor-β-activated kinase 1 (TAK1) is an upstream kinase regulating these pathways.
  • TAK1 plays a significant role in innate immunity, responding to microbial components and host signals.

Purpose of the Study:

  • To review recent advances in the activation mechanisms of TAK1.
  • To highlight the diverse physiological functions of TAK1.
  • To explore the therapeutic potential of targeting TAK1.

Main Methods:

  • Literature review of recent research on TAK1.
  • Analysis of TAK1's role in various cellular signaling pathways.
  • Examination of TAK1's involvement in immune and inflammatory responses.

Main Results:

  • TAK1 is a central regulator activated by various stimuli.
  • TAK1 mediates critical inflammatory and immune responses.
  • Recent studies reveal complex activation mechanisms and broad physiological roles.

Conclusions:

  • TAK1 is a pivotal kinase in cellular signaling, immunity, and inflammation.
  • Understanding TAK1 activation and function is key for therapeutic development.
  • Targeting TAK1 presents promising strategies for treating inflammatory disorders and cancer.

More Related Videos

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo08:19

Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo

Published on: July 20, 2019

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
Transducer Mechanism: Enzyme-Linked Receptors01:27

Transducer Mechanism: Enzyme-Linked Receptors

Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
NF-κB-dependent Signaling Pathway02:26

NF-κB-dependent Signaling Pathway

The transcription factor NF-κB was discovered in 1986 in the lab of Nobel laureate Professor David Baltimore, for its interaction with the immunoglobulin light chain enhancer in B-cells. After more than three decades of study, it is now evident that NF-κB regulates the expression of over 100 genes. Most of these genes play an essential role in the innate and adaptive immune responses as well as the inflammatory responses of animals.
NF-κB-dependent Signaling Mechanism
The heterodimer of NF-κB...